These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 25260824)

  • 81. [Clinical study of induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of FLT3-ITD(+) acute myeloid leukemia with normal karyotype].
    Li F; Liu YP; Zhu H; Hong M; Qian SX; Zhu Y; Shen WY; Chen LJ; He GS; Wu HX; Lu H; Li JY; Miao KR
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):230-235. PubMed ID: 37356985
    [No Abstract]   [Full Text] [Related]  

  • 82. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma.
    Shimizu H; Saitoh T; Tanaka M; Mori T; Sakura T; Kawai N; Kanda Y; Nakaseko C; Yano S; Fujita H; Fujisawa S; Miyawaki S; Kanamori H; Okamoto S
    Leukemia; 2012 Dec; 26(12):2469-73. PubMed ID: 22699453
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
    Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Interactive diagnostics in the indication to allogeneic SCT in AML.
    Bacher U; Haferlach C; Schnittger S; Kern W; Kroeger N; Zander AR; Haferlach T
    Bone Marrow Transplant; 2009 May; 43(10):745-56. PubMed ID: 19363529
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
    Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
    Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
    [TBL] [Abstract][Full Text] [Related]  

  • 87. RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia.
    Xiao J; Xie J; Zhou B; Liu Y; Lu J; Jiang A; Yao H; Qiu Q; Ding Z; Xue S; Tang X; Qiu H; Chen S; Shen H; Wu D; Xu Y
    Leuk Lymphoma; 2023 May; 64(5):951-961. PubMed ID: 36964663
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.
    Chen F; Sun J; Yin C; Cheng J; Ni J; Jiang L; Wang Q; Yu G; Wei Y; Liu X; Sun J; Carter BZ; Jiang X
    Bone Marrow Transplant; 2020 Apr; 55(4):740-748. PubMed ID: 31645666
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
    Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
    Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT).
    Doubek M; Muzík J; Szotkowski T; Koza V; Cetkovský P; Kozák T; Zák P; Voglová J; Struncová S; Dusek L; Indrák K
    Neoplasma; 2007; 54(1):89-94. PubMed ID: 17233551
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
    Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
    Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.
    Aoki J; Ishiyama K; Taniguchi S; Fukuda T; Ohashi K; Ogawa H; Kanamori H; Eto T; Iwato K; Sakamaki H; Morishima Y; Nagamura T; Atsuta Y; Takami A
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2029-33. PubMed ID: 25196856
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.
    Wan L; Ding S; Xu M; Lv K; Du Y; Wu D; Xu M; Liu Y
    Int J Hematol; 2022 Nov; 116(5):731-743. PubMed ID: 35857193
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
    Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
    [TBL] [Abstract][Full Text] [Related]  

  • 95. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
    Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
    Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
    Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
    Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
    Pfirrmann M; Ehninger G; Thiede C; Bornhäuser M; Kramer M; Röllig C; Hasford J; Schaich M;
    Lancet Oncol; 2012 Feb; 13(2):207-14. PubMed ID: 22197676
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].
    Wu TM; Xue SL; Li Z; Yu JQ; Wang J; Wang BR; Wan CL; Shen XD; Qiu QC; Bao XB; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):646-653. PubMed ID: 34547870
    [No Abstract]   [Full Text] [Related]  

  • 99. Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission.
    Choi Y; Lee JH; Lee JH; Park HS; Choi EJ; Jo JC; Lee YJ; Lee YS; Kang YA; Lee KH
    Eur J Haematol; 2020 Sep; 105(3):262-273. PubMed ID: 32353911
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years.
    Zhang Y; Zhang Y; Chen Q; Tang G; Zhang W; Yang J; Wang J; Hu X
    Ann Hematol; 2019 Apr; 98(4):997-1007. PubMed ID: 30607578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.